Jessica Hope Roark

Array ( [id] => 10347535 [patent_doc_number] => 20150232540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'ANALYSIS OF UBIQUITNATED POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/572194 [patent_app_country] => US [patent_app_date] => 2014-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 18998 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14572194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10262281 [patent_doc_number] => 20150147278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-28 [patent_title] => 'ANTIBODY AGAINST TRANSPORTER AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/561944 [patent_app_country] => US [patent_app_date] => 2014-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13314 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14561944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182219 [patent_doc_number] => 10106611 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Antibodies that bind to MHC class I polypeptide-related sequence A [patent_app_type] => utility [patent_app_number] => 15/100060 [patent_app_country] => US [patent_app_date] => 2014-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 95 [patent_no_of_words] => 45715 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15100060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9916724 [patent_doc_number] => 20150071929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'ANTI-NKG2A ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/548327 [patent_app_country] => US [patent_app_date] => 2014-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 33124 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14548327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10663679 [patent_doc_number] => 20160009823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT' [patent_app_type] => utility [patent_app_number] => 14/539009 [patent_app_country] => US [patent_app_date] => 2014-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 104 [patent_figures_cnt] => 104 [patent_no_of_words] => 46668 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14539009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10663679 [patent_doc_number] => 20160009823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT' [patent_app_type] => utility [patent_app_number] => 14/539009 [patent_app_country] => US [patent_app_date] => 2014-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 104 [patent_figures_cnt] => 104 [patent_no_of_words] => 46668 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14539009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9908979 [patent_doc_number] => 20150064180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND MTOR INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/537753 [patent_app_country] => US [patent_app_date] => 2014-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8142 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14537753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9908991 [patent_doc_number] => 20150064191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'ANTI-C-MET-ANTIBODY FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 14/534085 [patent_app_country] => US [patent_app_date] => 2014-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 35474 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14534085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11092364 [patent_doc_number] => 20160289332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/034992 [patent_app_country] => US [patent_app_date] => 2014-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 48264 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15034992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067706 [patent_doc_number] => 20160264670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'IMMUNOTHERAPEUTIC DOSING REGIMENS AND COMBINATIONS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/035080 [patent_app_country] => US [patent_app_date] => 2014-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 28647 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15035080 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11060788 [patent_doc_number] => 20160257750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'COMBINATION OF ANTI-KIR AND ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE MYELOMA' [patent_app_type] => utility [patent_app_number] => 15/032919 [patent_app_country] => US [patent_app_date] => 2014-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 23143 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15032919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15309113 [patent_doc_number] => 10519247 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Targeting HER2 and HER3 with bispecific antibodies in cancerous cells [patent_app_type] => utility [patent_app_number] => 15/023648 [patent_app_country] => US [patent_app_date] => 2014-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 13663 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15023648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10233257 [patent_doc_number] => 20150118251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS' [patent_app_type] => utility [patent_app_number] => 14/529719 [patent_app_country] => US [patent_app_date] => 2014-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 15223 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14529719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13916693 [patent_doc_number] => 10202454 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-12 [patent_title] => Anti-PD-L1 monoclonal antibodies and fragments thereof [patent_app_type] => utility [patent_app_number] => 15/029369 [patent_app_country] => US [patent_app_date] => 2014-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 40441 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15029369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11319392 [patent_doc_number] => 09518130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-13 [patent_title] => 'Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers' [patent_app_type] => utility [patent_app_number] => 14/518900 [patent_app_country] => US [patent_app_date] => 2014-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 10624 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14518900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11060786 [patent_doc_number] => 20160257748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'V-C-FC-V-C ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/916207 [patent_app_country] => US [patent_app_date] => 2014-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 23706 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14916207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9916723 [patent_doc_number] => 20150071928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/491459 [patent_app_country] => US [patent_app_date] => 2014-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16397 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14491459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10714206 [patent_doc_number] => 20160060353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'ANTI-HER2 ANTIBODY VARIANTS' [patent_app_type] => utility [patent_app_number] => 14/489810 [patent_app_country] => US [patent_app_date] => 2014-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 30924 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14489810 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11487098 [patent_doc_number] => 09593162 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-14 [patent_title] => 'Internalizing human monoclonal antibodies targeting prostate cancer cells in situ' [patent_app_type] => utility [patent_app_number] => 14/486943 [patent_app_country] => US [patent_app_date] => 2014-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 26818 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14486943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9798554 [patent_doc_number] => 20150010498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-08 [patent_title] => 'Immunocytokines for Cancer Treatment in Combination with Chemotherapeutic Agents' [patent_app_type] => utility [patent_app_number] => 14/457522 [patent_app_country] => US [patent_app_date] => 2014-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5450 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14457522 [rel_patent_id] =>[rel_patent_doc_number] =>)